Advanced Filters
noise

Torino, Piemonte, Italy Clinical Trials

A listing of Torino, Piemonte, Italy clinical trials actively recruiting patients volunteers.

Found 337 clinical trials

First-In-Human Clinical Study for Treatment of Severe Mitral Valve INsufficiency With Epygon™ TRanscatheter Mitral VAlve System

The EPYGON VALVE is an innovative mitral valve, intended for valve replacement of a native mitral valve through a minimally invasive implant procedure by means of a dedicated implant device. The EPYGON VALVE is a bio prosthesis, composed by a functional assembly of bovine pericardium on a NiTinol stent. The …

60 years of age All Phase N/A
F Felicetto T Ferrara

Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

MRD driven study. Addition of gemtuzumab to conventional chemotherapy to reduce MRD of patients with favorable/intermediate-risk AML. Post-consolidation assessment of MRD.

18 - 60 years of age All Phase 3
M Massimo Breccia, MD

Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)

Open-label, randomized multicenter phase III non-inferiority study

18 - 70 years of age All Phase 3

Safety and Efficacy of Adaptive Deep Brain Stimulation

The aim of this study is to assess the safety and the potential efficacy of personalized Local Field Potential (LFP)-based adaptive Deep Brain Stimulation (aDBS), using the implantable pulse generator (IPG) of the "AlphaDBS" System, in Parkinson's Disease patients, chronically implanted in subthalamic nucleus (STN) for DBS.

years of age All Phase N/A
D Daniela E Cilloni

Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study.

This study aims to observe inflammatory biomarkers and their trend over the history of the disease in patients suffering from MPN Ph negative; it also wants to identify any correlations between the aforementioned biomarkers and disease outcomes, considering first of all the occurrence of thrombo-haemorrhagic events and the evolution in …

18 - 99 years of age All Phase N/A

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

This is a multicenter, single arm, phase II study aimed at evaluating ibrutinib therapy for the treatment of AIHA in patients with CLL/SLL or CLL-like MBL.

18 years of age All Phase 2
F Francesco Notaristefano, MD

In-hospital Stellate Ganglion Block for Arrhythmic Storm

Arrhythmic storm is a real emergency and its treatment could be challenging. Antiarrhythmic drugs are few and often ineffective. Neuromodulation has been grown in evidences but no large multicentric studies are present in literature about safety and effectiveness of Percutaneous Stellate Ganglion Block (PSGB). Patients with an electrical storm refractory …

years of age All Phase N/A
V Vanesa Gregorc

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

This study is being conducted to explore the immunological mechanism of action of Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor (CPI) therapy in multiple cancer types, as well as to obtain early information on the safety of this combination therapy.

18 years of age All Phase 1
M Melodie Aricò

Multicentre Prospective Observational Study of Acute Intoxications in Paediatric Age

Acute intoxications represent a major public health problem, especially when affect a population such as children, who are vulnerable and at greater risk of unintentional and preventable poisonings. The primary objective of the study is to assess the epidemiology of acute intoxications in paediatric age with respect to the social …

1 - 16 years of age All Phase N/A
I Ilaria Buondonno, PhD

INSIDE: Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations

400 patients will be enrolled and divided into 3 cohorts: Cohort A: patients with high risk localized prostate cancer (PC) defined as \>cT3 or PSA \> 20 ng/mL or presence of ECE or SVI at mpMRI; Cohort B: patients with de novo metastatic hormone sensitive prostate cancer (mHSPC); Cohort C: …

18 years of age Male Phase N/A

Simplify language using AI